Laure Grelier1, Michael Baboudjian2, Bastien Gondran-Tellier2, Anne-Laure Couderc3, Robin McManus2, Jean-Laurent Deville4, Ana Carballeira5, Raphaelle Delonca2, Veronique Delaporte2, Laetitia Padovani1, Romain Boissier2, Eric Lechevallier2, Xavier Muracciole1. 1. Department of Urology and Kidney Transplantation, Aix-Marseille University, Assistance Publique-Hôpitaux de Marseille (AP-HM), Conception Academic Hospital, 13005 Marseille, France. 2. Department of Radiotherapy, La Timone Hospital, Assistance Publique-Hopitaux de Marseille (AP-HM), 13005 Marseille, France. 3. Internal Medicine, Geriatrics and Therapeutic University, Assistance Publique-Hopitaux de Marseille (AP-HM), 13005 Marseille, France. 4. Department of Oncology, La Timone Hospital, Aix-Marseille University, Assistance Publique-Hopitaux de Marseille (AP-HM), 13005 Marseille, France. 5. Department of Radiology, Aix-Marseille University, Assistance Publique-Hopitaux de Marseille (AP-HM), Conception Academic Hospital, 13005 Marseille, France.
Abstract
INTRODUCTION: The aim of this study was to report the oncological outcomes and toxicity of stereotactic body radiotherapy (SBRT) to treat primary renal cell carcinoma (RCC) in frail patients unfit for surgery or standard alternative ablative therapies. METHODS: We retrospectively enrolled 23 patients who had SBRT for primary, biopsy-proven RCC at our tertiary center between October 2016 and March 2020. Treatment-related toxicities were defined using CTCAE, version 4.0. The primary outcome was local control which was defined using the Response Evaluation Criteria in Solid Tumors. RESULTS: The median age, Charlson score and tumor size were 81 (IQR 79-85) years, 7 (IQR 5-8) and 40 (IQR 28-48) mm, respectively. The most used dose fractionation schedule was 35 Gy (78.3%) in five or seven fractions. The median duration of follow-up for all living patients was 22 (IQR 10-39) months. Local recurrence-free survival, event-free survival, cancer-specific survival and overall survival were 96 (22/23), 74 (18/23), 96 (22/23) and 83% (19/23), respectively. There were no grade 3-4 side effects. No patients required dialysis during the study period. No treatment-related deaths or late complications were reported. CONCLUSION: SBRT appears to be a promising alternative to surgery or ablative therapy to treat primary RCC in frail patients.
INTRODUCTION: The aim of this study was to report the oncological outcomes and toxicity of stereotactic body radiotherapy (SBRT) to treat primary renal cell carcinoma (RCC) in frail patients unfit for surgery or standard alternative ablative therapies. METHODS: We retrospectively enrolled 23 patients who had SBRT for primary, biopsy-proven RCC at our tertiary center between October 2016 and March 2020. Treatment-related toxicities were defined using CTCAE, version 4.0. The primary outcome was local control which was defined using the Response Evaluation Criteria in Solid Tumors. RESULTS: The median age, Charlson score and tumor size were 81 (IQR 79-85) years, 7 (IQR 5-8) and 40 (IQR 28-48) mm, respectively. The most used dose fractionation schedule was 35 Gy (78.3%) in five or seven fractions. The median duration of follow-up for all living patients was 22 (IQR 10-39) months. Local recurrence-free survival, event-free survival, cancer-specific survival and overall survival were 96 (22/23), 74 (18/23), 96 (22/23) and 83% (19/23), respectively. There were no grade 3-4 side effects. No patients required dialysis during the study period. No treatment-related deaths or late complications were reported. CONCLUSION: SBRT appears to be a promising alternative to surgery or ablative therapy to treat primary RCC in frail patients.